Fact based stock research
Kobayashi Pharmaceutical (TSE:4967)
JP3301100008
Kobayashi Pharmaceutical stock research in summary
Kobayashi Pharmaceutical shares are more expensive than other comparable stocks. While they are safely financed, they show below average growth, and are poor value. We recommend evaluating whether the future of the company Kobayashi Pharmaceutical is really as positive as the high price of the shares suggests. If you come to the conclusion that the future for this company is only average, that could be a reason to sell this share.
Latest Obermatt Ranks
Value Rank | 24 | ![]() |
Growth Rank | 33 | ![]() |
Safety Rank | 86 | ![]() |
Combined Rank | 50 | ![]() |
Country | Japan |
Industry | Personal Products |
Index | |
Size class | Large |
March 26, 2021. Stock data may be delayed. Login to get the most recent research.
Google: Kobayashi Pharmaceutical
Research History: Kobayashi Pharmaceutical
RESEARCH HISTORY | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
VALUE | ||||||||
VALUE | n/a |
![]() |
n/a |
![]() |
30 |
![]() |
24 |
![]() |
GROWTH | ||||||||
GROWTH | n/a |
![]() |
n/a |
![]() |
57 |
![]() |
33 |
![]() |
SAFETY | ||||||||
SAFETY | n/a |
![]() |
n/a |
![]() |
89 |
![]() |
86 |
![]() |
COMBINED | ||||||||
COMBINED | n/a |
![]() |
n/a |
![]() |
72 |
![]() |
50 |
![]() |
Value Metrics in Detail
VALUE METRICS | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
PRICE VS. REVENUES (P/S) | ||||||||
PRICE VS. REVENUES (P/S) | n/a |
![]() |
n/a |
![]() |
23 |
![]() |
31 |
![]() |
PRICE VS. PROFITS (P/E) | ||||||||
PRICE VS. PROFITS (P/E) | n/a |
![]() |
n/a |
![]() |
45 |
![]() |
35 |
![]() |
PRICE VS. CAPITAL (Market-to-Book) | ||||||||
PRICE VS. CAPITAL (Market-to-Book) | n/a |
![]() |
n/a |
![]() |
14 |
![]() |
24 |
![]() |
DIVIDEND YIELD | ||||||||
DIVIDEND YIELD | n/a |
![]() |
n/a |
![]() |
57 |
![]() |
50 |
![]() |
CONSOLIDATED RANK: VALUE | ||||||||
CONSOLIDATED RANK: VALUE | n/a |
![]() |
n/a |
![]() |
30 |
![]() |
24 |
![]() |
Growth Metrics in Detail
GROWTH METRICS | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
REVENUE GROWTH | ||||||||
REVENUE GROWTH | n/a |
![]() |
n/a |
![]() |
32 |
![]() |
12 |
![]() |
PROFIT GROWTH | ||||||||
PROFIT GROWTH | n/a |
![]() |
n/a |
![]() |
57 |
![]() |
33 |
![]() |
STOCK RETURNS | ||||||||
STOCK RETURNS | n/a |
![]() |
n/a |
![]() |
82 |
![]() |
88 |
![]() |
CONSOLIDATED RANK: GROWTH | ||||||||
CONSOLIDATED RANK: GROWTH | n/a |
![]() |
n/a |
![]() |
57 |
![]() |
33 |
![]() |
Safety Metrics in Detail
SAFETY METRICS | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
LEVERAGE | ||||||||
LEVERAGE | n/a |
![]() |
n/a |
![]() |
69 |
![]() |
66 |
![]() |
REFINANCING | ||||||||
REFINANCING | n/a |
![]() |
n/a |
![]() |
35 |
![]() |
30 |
![]() |
LIQUIDITY | ||||||||
LIQUIDITY | n/a |
![]() |
n/a |
![]() |
100 |
![]() |
100 |
![]() |
CONSOLIDATED RANK: SAFETY | ||||||||
CONSOLIDATED RANK: SAFETY | n/a |
![]() |
n/a |
![]() |
89 |
![]() |
86 |
![]() |
Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Kobayashi Pharmaceutical from March 26, 2021.
We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.